Europe

Finland, UNRISD and the WHO asked what the Economics of Health for All strategy means for the next generation, from intergenerational fairness and participatory foresight to dignified access to care. #SyenzaNews #HealthEconomics #WellbeingEconomy

France reimbursed 90% of drug costs in 2024, yet many patients still feel shortchanged. Maurice-Pierre Planel breaks down the numbers behind the paradox. #SyenzaNews #MarketAccess #PharmaPolicy

EMA has authorised Ablymico, a synthetic liraglutide for weight management. The approval, granted on 15 July 2026, covers adults, adolescents and children from age six. Ablymico is bioequivalent to Saxenda but is produced by chemical synthesis rather than living cells. #SyenzaNews #MarketAccess #Obesity #GLP1

The HTAi 2026 Annual Meeting in Istanbul drew 780+ delegates from 64 countries to reframe HTA as a system shaper, not just an evaluator of technologies.

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have opened a public consultation on a draft EMRN data standards framework, the governance document that will shape how the European medicines regulatory network adopts, creates, updates, and implements data standards for human and veterinary medicines. The draft, published under reference EMA/185661/2026 and dated 1 July 2026, is open for comment from 17 August to 18 September 2026. Responses go through an EUSurvey form linked in the consultation […]

Weill Cornell researchers have proposed ASTRA, a multi-agent system that would delegate routine clinical trial work to AI agents while human experts keep the final say on clinical and regulatory decisions.

The European Commission has approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making Trodelvy the first ADC-based backbone across PD-L1 status.

A new consensus framework grades dehiscence, infection, seroma, and haematoma in a single score, with strong agreement across 60 specialists.

Portugal medicinal cannabis exports reached 66,305 kg in the first half of 2026, according to INFARMED, already 83% of the 79,883 kg shipped across all of 2025. The country’s medicines regulator published the figures in its mid-year report on the sector, which also shows cultivation and manufacturing licences easing back after several years of rapid expansion. Portugal began regulating medicinal cannabis in 2018, when the Assembly of the Republic approved a law covering marketing authorisations, prescribing and pharmacy dispensing. A […]

💊 Can generic medicines deliver €300 million in savings for Portugal? Portugal is targeting major cost reductions in its healthcare system by accelerating the uptake of generic medicines, aiming to improve affordability and sustainability. This move highlights strategic efforts in market access and cost-effectiveness within the pharmaceutical sector. Read the full analysis to see what it means for stakeholders. #SyenzaNews #pharmaceuticals #MarketAccess #costeffectiveness

📉 Why are EMA orphan authorisations set to drop in 2026? Latest statistics reveal a significant decline in orphan medicinal product authorisations by the European Medicines Agency, raising questions about the future pipeline for rare disease therapies. This trend could reshape drug development priorities across Europe. Read the full analysis to understand the implications for patients and industry. #SyenzaNews #pharmaceuticals #regulatoryaffairs #innovation #MarketAccess

How can blended capital unlock breakthroughs in pediatric cancer treatments? Developing drugs for childhood cancers faces unique challenges—small patient populations, high risks, and limited commercial returns often deter traditional investors. This article examines why combining public grants, venture funding, and philanthropic support is critical to advancing therapies in oncology. Read the full analysis to explore innovative financing models driving progress. #SyenzaNews #oncology #biotechnology #innovation #HealthEconomics